Exscientia Future Growth
Future criteria checks 1/6
Exscientia's earnings are forecast to decline at 20.2% per annum while its annual revenue is expected to grow at 18.5% per year. EPS is expected to decline by 13.1% per annum.
Key information
-20.2%
Earnings growth rate
-13.1%
EPS growth rate
Biotechs earnings growth | 25.1% |
Revenue growth rate | 18.5% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 18 May 2024 |
Recent future growth updates
Recent updates
Exscientia: Drug Discovery Platform Attracting Partners And Cash
May 22Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade)
Feb 26Is Exscientia (NASDAQ:EXAI) In A Good Position To Invest In Growth?
Jan 11Earnings Update: Exscientia plc (NASDAQ:EXAI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 12New Forecasts: Here's What Analysts Think The Future Holds For Exscientia plc (NASDAQ:EXAI)
Aug 31We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate
Aug 25Broker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging Higher
Jul 21Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans
Apr 22We're Not Very Worried About Exscientia's (NASDAQ:EXAI) Cash Burn Rate
Dec 30The Exscientia plc (NASDAQ:EXAI) Analysts Have Been Trimming Their Sales Forecasts
Aug 31Exscientia: Using AI To Power Drug Development
Aug 15Companies Like Exscientia (NASDAQ:EXAI) Can Afford To Invest In Growth
May 29Exscientia: Drug Discovery Using AI For Sanofi And Self-Owned Pipeline
Apr 12Bullish: Analysts Just Made A Sizeable Upgrade To Their Exscientia plc (NASDAQ:EXAI) Forecasts
Jan 09Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 44 | N/A | N/A | N/A | 1 |
12/31/2025 | 62 | -243 | N/A | N/A | 3 |
12/31/2024 | 74 | -236 | N/A | N/A | 3 |
3/31/2024 | 25 | -163 | -166 | -133 | N/A |
12/31/2023 | 26 | -186 | -184 | -150 | N/A |
9/30/2023 | 30 | -176 | -238 | -202 | N/A |
6/30/2023 | 28 | -188 | -261 | -219 | N/A |
3/31/2023 | 32 | -174 | -147 | -109 | N/A |
12/31/2022 | 33 | -144 | -100 | -73 | N/A |
9/30/2022 | 27 | -111 | -51 | -31 | N/A |
6/30/2022 | 44 | -84 | 3 | 21 | N/A |
3/31/2022 | 38 | -78 | -30 | -18 | N/A |
12/31/2021 | 37 | -67 | -19 | -9 | N/A |
9/30/2021 | 37 | -48 | -9 | 1 | N/A |
6/30/2021 | 15 | -54 | -21 | -15 | N/A |
3/31/2021 | 17 | -33 | -43 | -37 | N/A |
12/31/2020 | 13 | -30 | -33 | -29 | N/A |
12/31/2019 | 12 | -8 | 7 | 9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EXAI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: EXAI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: EXAI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: EXAI's revenue (18.5% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: EXAI's revenue (18.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EXAI's Return on Equity is forecast to be high in 3 years time